Poxel S.A. (PXXLF)

5.82 0.00 (0.00%) At close: 10:29AM EST

Poxel S.A.

Immeuble Le Sunway
259-261 Avenue Jean Jaurès
Lyon 69007
France
33 4 37 37 20 10
https://www.poxelpharma.com

Sector(s): 
Industry: 
Full Time Employees: 52

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Thomas Kuhn M.B.A., Pharm.D., Pharm D MBA	Co-Founder, CEO & Director	450.43k	N/A	N/A
Dr. Sébastien Bolze Ph.D., Pharm.D., Pharm D Ph.D.	Co-Founder, COO & Exec. VP	N/A	N/A	N/A
Dr. Pascale Fouqueray-Grellier M.D., Ph.D.	Co-Founder and Exec. VP of Clinical Devel. & Regulatory Affairs	N/A	N/A	N/A
Dr. Sophie Hallakou-Bozec Ph.D.	Co-Founder and Sr. VP of R&D Pharmacology & Scientific Communication	N/A	N/A	N/A
Ms. Anne Renevot	Exec. VP & CFO	N/A	N/A	N/A
Dr. David E. Moller M.D.	Exec. VP & Chief Scientific Officer	N/A	N/A	N/A
Ms. Elizabeth Woo M.B.A.	Sr. VP of Investor Relations, Corp. Communications & PR	N/A	N/A	N/A
Mr. Quentin Durand	Exec. VP & Chief Legal Officer	N/A	N/A	N/A
Sylvie Bertrand	VP of HR	N/A	N/A	N/A
Mr. Noah D. Beerman MBA	Exec. VP of Bus. Devel. & Pres of US Operations	N/A	N/A	1962

Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Poxel S.A., a clinical-stage biopharmaceutical company, develops novel treatments for metabolic diseases, type 2 diabetes, and liver diseases. The company's lead product is Imeglimin, an oral drug candidate, which completed Phase III clinical development stage in Japan, as well as in Phase III in the United States and Europe for the treatment of type 2 diabetes that improves pancreatic beta cell function, reduces insulin resistance, and decreases cardiovascular and metabolic disease risk factors, such as heightened blood lipid levels and excess body weight. It also develops PXL770, an adenosine monophosphate-activated protein kinase enzyme, which is in a Phase 2a clinical trial that treats chronic metabolic diseases, including diseases that affect the liver, such as non-alcoholic steatohepatitis (NASH). The company has a licensing agreement with Enyo Pharma S.A.S. for the development of PXL007 (EYP001), a synthetic non-steroidal and non-bile acid FXR agonist that is in Phase II study for the treatment of hepatitis B and NASH; and DeuteRx LLC for the development of PXL065, a mitochondrial pyruvate carrier inhibitor, which is in a phase I clinical trial for the treatment of NASH. Poxel S.A. was incorporated in 2009 and is headquartered in Lyon, France.

Corporate Governance

Poxel S.A.’s ISS Governance QualityScore as of September 26, 2021 is 10. The pillar scores are Audit: 10; Board: 8; Shareholder Rights: 4; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.